Cantor Fitzgerald Maintains Hold On Sunesis Pharma, Sees 6% Downside For The Stock
In a research note published this morning, Cantor Fitzgerald analyst Mara Goldstein maintained a Hold rating on Sunesis Pharmaceuticals (NASDAQ:SNSS) with a $2 price target, which represents a 6% downside from where the stock is currently trading.
Goldstein wrote, “VALOR, the Phase III study of Qinprezo in patients with relapsed/refractory AML has been accepted for a late-breaking presentation at ASH, December 6-9, which we see as a positive sign for the shares. With the shares having been under substantial pressure following the revelation that the trial narrowly missed statistical significance of overall survival (OS) in the all-comer population, we view ASH to be the ideal venue for this presentation, as it will provide a real-time opportunity to see how the clinical community responds to the pre-stratified subset analysis. This opens the door, in our view, to investors warming up to the possibility of a U.S. regulatory path forward for Qinprezo.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Mara Goldstein has a total average return of 16.5% and a 70% success rate. Goldstein has a 35.2% average return when recommending SNSS, and is ranked #368 out of 3393 analysts.